In contrast to much of the transformation that can occur in the biotech world, MorphoSys AG’s strategic shift from provider of antibody technologies to developer of proprietary antibody therapeutics has occurred at a comparably glacial pace.
Years ago – around the time it signed a blockbuster antibody discovery deal with Novartis AG in 2007 –...